Key statistics
On Friday, Organon & Co (OGN:NYQ) closed at 8.21, 32.85% above the 52 week low of 6.18 set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.16 |
|---|---|
| High | 8.43 |
| Low | 7.98 |
| Bid | 8.15 |
| Offer | 8.64 |
| Previous close | 8.10 |
| Average volume | 4.67m |
|---|---|
| Shares outstanding | 259.98m |
| Free float | 259.32m |
| P/E (TTM) | 4.21 |
| Market cap | 2.11bn USD |
| EPS (TTM) | 1.92 USD |
| Annual div (ADY) | 0.08 USD |
|---|---|
| Annual div yield (ADY) | 0.99% |
| Div ex-date | Nov 20 2025 |
| Div pay-date | Dec 11 2025 |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
- Organon Completes Divestiture of JADA® System to Laborie
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
- Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
- Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
- Organon Reports Results for the Third Quarter Ended September 30, 2025
More ▼
